A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00699283
Recruitment Status : Terminated (An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected)
First Posted : June 17, 2008
Results First Posted : January 18, 2017
Last Update Posted : April 3, 2018
Information provided by (Responsible Party):
UCB Pharma

Brief Summary:
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Brivaracetam Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
Study Start Date : August 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures

Arm Intervention/treatment
Experimental: Brivaracetam (BRV) 1
50 mg daily
Drug: Brivaracetam
25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Name: ucb 34714

Experimental: Brivaracetam (BRV) 2
100 mg daily
Drug: Brivaracetam
25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
Other Name: ucb 34714

Primary Outcome Measures :
  1. The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase [ Time Frame: From Visit 4 (week 1) to the end of the Evaluation Period (week 17) (approximately 16 weeks) ]
    The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects from 16 to 75 years, both inclusive
  • Well-characterized focal epilepsy or epileptic syndrome
  • Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period
  • Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose

Exclusion Criteria:

  • Seizure type IA non-motor as only seizure type
  • History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline
  • Other serious uncontrolled disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00699283

  Hide Study Locations
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Garden Grove, California, United States
Loma Linda, California, United States
Newport Beach, California, United States
Riverside, California, United States
Sacramento, California, United States
Stanford, California, United States
United States, Colorado
Denver, Colorado, United States
Fort Collins, Colorado, United States
United States, Connecticut
Danbury, Connecticut, United States
New Haven, Connecticut, United States
Waterbury, Connecticut, United States
United States, Florida
Gainesville, Florida, United States
Miami, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Danville, Indiana, United States
Elkhart, Indiana, United States
United States, Maryland
Waldorf, Maryland, United States
United States, Michigan
Grand Rapids, Michigan, United States
United States, Missouri
Columbia, Missouri, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Flushing, New York, United States
Schenectady, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
United States, Ohio
Oberlin, Ohio, United States
Westerville, Ohio, United States
United States, Oklahoma
Tulsa, Oklahoma, United States
United States, Pennsylvania
Bethlehem, Pennsylvania, United States
Jenkintown, Pennsylvania, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, Texas
Austin, Texas, United States
Bedford, Texas, United States
San Antonio, Texas, United States
United States, Utah
Layton, Utah, United States
Ogden, Utah, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Bluefield, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
United States, Wisconsin
Marshfield, Wisconsin, United States
Bethune, France
Lille, France
Saint Brieuc, France
Toulouse, France
Berlin, Germany
Bernau, Germany
Bielefeld, Germany
Munchen, Germany
Munster, Germany
Ulm, Germany
Budapest, Hungary
Debrecen, Hungary
Kecskemet, Hungary
Szeged, Hungary
Bergamo, Italy
Firenze, Italy
Germaneto, Italy
Messina, Italy
Perugia, Italy
Pisa, Italy
Torino, Italy
Barcelona, Spain
Madrid, Spain
Murcia, Spain
Zaragoza, Spain
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)

Publications of Results:
Responsible Party: UCB Pharma Identifier: NCT00699283     History of Changes
Other Study ID Numbers: N01306
2008-000145-58 ( EudraCT Number )
First Posted: June 17, 2008    Key Record Dates
Results First Posted: January 18, 2017
Last Update Posted: April 3, 2018
Last Verified: March 2018

Keywords provided by UCB Pharma:
Epilepsy; Monotherapy
Partial Onset Seizures
Adults and Adolescents

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms